Compass Ion Advisors LLC Sells 93 Shares of Johnson & Johnson (NYSE:JNJ)

Compass Ion Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,885 shares of the company’s stock after selling 93 shares during the period. Compass Ion Advisors LLC’s holdings in Johnson & Johnson were worth $2,355,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Norges Bank bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $4,071,642,000. Wellington Management Group LLP increased its stake in shares of Johnson & Johnson by 16.4% in the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after acquiring an additional 3,391,657 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Johnson & Johnson by 7,875.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after acquiring an additional 2,064,175 shares during the period. Janney Montgomery Scott LLC bought a new position in Johnson & Johnson during the fourth quarter worth $193,050,000. Finally, Global Assets Advisory LLC acquired a new stake in Johnson & Johnson in the first quarter worth $170,372,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.2 %

JNJ stock opened at $146.42 on Tuesday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The stock has a market cap of $352.39 billion, a P/E ratio of 9.13, a P/E/G ratio of 2.43 and a beta of 0.52. The stock’s fifty day simple moving average is $148.14 and its two-hundred day simple moving average is $154.05. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.68 earnings per share. Analysts expect that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.39%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price on the stock. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.